Pembrolizumab plus gemcitabine and cisplatin improves survival in advanced biliary tract cancer
1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). ...
1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). ...
1. Patients who received adjuvant S-1 had prolonged overall survival and relapse-free survival compared to those who were managed with ...
1. Using futibatinib to treat patients with FGFR mutated intrahepatic cholangiocarcinoma resulted in a 42% objective response rate (partial or ...
1. Patients receiving Ivosidenib had longer overall survival as compared to patients on placebo. 2. Quality of life measures favored ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.